InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Lamy Patrick, See Remarks. Officer active across 1 company, notably Akero Therapeutics, Inc.. Cumulatively, 17 filings have been recorded. Breakdown: 0 buy · 5 sells. Total volume traded: €213k. History available since 8 December 2023. The latest transaction was filed on 1 July 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Lamy Patrick
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations17 total
3,059 sharesCommon StockSEC:0001193125-25-312099:0
26,832 sharesCommon StockSEC:0001193125-25-312099:1
2,000 shares@ US$52.8813.9% of flowCommon StockSEC:0000950170-25-094011:0
193 shares@ US$23.8680.7% of flowCommon StockSEC:0000950170-25-093320:0
875 shares@ US$54.597.5% of flowCommon StockSEC:0000950170-25-088639:0
2,000 shares@ US$19.876.2% of flowCommon StockSEC:0000950170-25-088206:0
919 shares@ US$53.9999.1% of flowCommon StockSEC:0000950170-25-085670:0
4,000 shares@ US$19.8716.0% of flowCommon StockSEC:0000950170-25-081774:0
4,000 shares@ US$44.3743.2% of flowCommon StockSEC:0000950170-25-077131:0
8,000 shares@ US$19.8738.6% of flowCommon StockSEC:0000950170-25-068392:0
1,000 shares@ US$19.875.2% of flowCommon StockSEC:0000950170-25-033997:0
234 shares@ US$19.6861.2% of flowCommon StockSEC:0000950170-25-010706:0
17,400 shares0Common StockSEC:0000950170-24-138149:0
925 shares@ US$30.797.4% of flowCommon StockSEC:0000950170-24-136020:0
221 shares@ US$19.9411.1% of flowCommon StockSEC:0000950170-24-080923:0
569 shares@ US$22.6413.3% of flowCommon StockSEC:0000950170-24-073183:0
18,570 shares0Common StockSEC:0000950170-23-069745:0
17 of 17 declarations
About Lamy Patrick
Patrick Lamy is involved in various functions at Akero Therapeutics, Inc. His role includes specific responsibilities that contribute to the development and strategy of the company. His expertise is an asset to the organization.
